ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Helius to Showcase Innovative PoNS Device at ACRM’s 2022 Conference – Demonstrating the Power of Neuromodulation to Help People with MS Improve their Gait

NEWTOWN, Pa., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies (NASDAQ: HSDT) will showcase its innovative new Portable Neuromodulation Stimulator (PoNS®) at the 99th annual American Congress of Rehabilitation Medicine (ACRM) Conference, held November 8-11 in Chicago. Visitors to booth 512 will see the device and learn more about how it can improve gait deficiency in people with multiple sclerosis (MS).

PoNS works by delivering electrical impulses through nerve fibers on the tongue, stimulating the flow of millions of neural impulses to the brain structures that control gait. This creates a cascade of activity in the brain that – when combined with an exercise regimen supervised by a physical therapist – produces a neuromodulatory and neuroplastic effect that can have a significant impact on the independence and personal productivity of people with MS. (Results of this study can be found at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017705/)

“The ACRM is committed to helping people live their fullest lives by improving, expanding and regaining mobility, and we’re excited to exhibit at the Conference because we share the same goals,” said Antonella Favit-Van Pelt, M.D., Ph.D., Helius' Chief Medical Officer. “PoNS addresses a complication that’s very top-of-mind for people with MS: 70% of them report having difficulty walking, and of that group 70% identify gait deficit as the most challenging aspect of their disease.”

In addition to seeing the PoNS device in person, booth visitors can speak with key Helius team members, who can answer questions about PoNS and the accompanying PoNS Therapy regimen that maximizes its effectiveness. Physical therapists also will be able to sign up for free, online PoNS Therapy training.

“Rehabilitation professionals who work with people with MS, or are interested in the relationship between neuromodulation and gait, are invited to visit us at booth 512,” said Favit-Van Pelt. “But this is more than just a chance to see the device and talk, it’s an opportunity to take action: By signing up for training physical therapists are making themselves even more invaluable to their patients with MS.”

About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS®). For more information, visit www.heliusmedical.com.

About the PoNS Device and PoNS Therapy
The Portable Neuromodulation Stimulator (PoNS) is an innovative non-surgical medical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to improve balance and gait. The PoNS device is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. Helius is advancing PoNS post-approval research in MS through a recently launched Therapeutic Experience Program (TEP) designed to partner with neurologists and neurorehabilitation therapists at 10-12 US centers of excellence, who express an interest in becoming “early adopters” of PoNS therapy. For more information visit www.ponstherapy.com.


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  231.32
+2.07 (0.90%)
AAPL  268.66
-0.34 (-0.13%)
AMD  260.57
+2.56 (0.99%)
BAC  52.86
-0.01 (-0.02%)
GOOG  272.71
+4.28 (1.59%)
META  750.46
-0.99 (-0.13%)
MSFT  538.66
-3.41 (-0.63%)
NVDA  206.34
+5.31 (2.64%)
ORCL  275.24
-5.59 (-1.99%)
TSLA  459.46
-1.09 (-0.24%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.